Status and phase
Conditions
Treatments
About
Aim of the study is evaluation of the efficacy of injectable platelet-rich plasma in orthodontic tooth movement acceleration with clear aligner
Full description
Malocclusion is frequently viewed as detrimental to one' self-worth and overall physical, social, and mental health. On the past few years, more and more grown-up patients have persued orthodontic care and they want attractive and pleasant options instead of traditional braces. CLEAR aligners that meet this need are also subject to technological advancements in the materials used and the methods of production. Consequently, CAT has merged as the leading trend in orthodontic innovation. The primary advateges of clear aligner therapy include the option to remove while eating, enhanced oral hygiene practices, less discomfort for patients,and the capability to visualize the treatment outcome through computer applications.
Clear aligners need to be removed during eating, when drinking hot beverages that may lead to warping, while having sugary beverages, and also when cleaning teeth.
Today, numerous methods have emerged to accelerate orthodontic tooth movement, encompassing invasive,minimally invasive,and non-invasive strategies.
IN addition, the use of medications and autologous biological solutions, like platelet-rich plasma, has been suggested.
One of the recently utilized local agents to accelerate the process of orthodontic tooth movement is platelet-rich plasma.
Platelet-rich plasma is characterized as an autologous concentration of platelets within a small quantity of plasma Prepared from blood centrifuging double spin.
The application of PRP has been used in regenerative dentistry and healing acceleration in oral surgery.
PRP serves as an abundant reservoir of cytokines and contains seven essential growth factors:
Also elevated levels of cytokine production during the process of bone remodelling could accelerate tooth movement.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 2 patient groups
Loading...
Central trial contact
Ali Mahmoud Elhewaity
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal